Induced pluripotent stem cell-derived mesenchymal stem cells activate quiescent T cells and elevate regulatory T cell response via NF-κB in allergic rhinitis patients

Stem Cell Research & Therapy

Song Guo Zheng¹  Xin Li²  Xue-Quan Deng³  Qing-Xiang Zeng³  Xing-Liang Fan³  Dong Chen³  Cheng-Lin Li³  Zhi-Bin Xu³  Jianbo Shi³  Qing-Ling Fu³ 

[1] Department of Clinical Immunology, The Third Affiliated Hospital, Sun Yat-sen University;Department of Emergency, Guangdong General Hospital, Guangdong Academy of Medical Science;Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University;

关键词: Induced pluripotent stem cell-derived mesenchymal stem cells;    Allergic rhinitis;    Quiescent T cells;    Immunomodulation;    NF-κB;   

DOI  :  10.1186/s13287-018-0896-z

来源: DOAJ

【 摘 要 】

Abstract Background It has been demonstrated previously that induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) have immunosuppressive effects on activated T cells. However, the effects of iPSC-MSCs on quiescent T cells are still unknown. The aim of this study was to identify the immunomodulatory role of iPSC-MSCs on resting peripheral blood mononuclear cells (PBMCs) from allergic rhinitis (AR) patients. Methods PBMCs were cocultured with iPSC-MSCs without any stimulation, following which lymphocyte proliferation, activation of T cells, TH1/TH2 and regulatory T (Treg) cell differentiation, and Treg cell function were analyzed. The roles of soluble factors and cell–cell contact were examined to investigate the mechanisms involved. Results iPSC-MSCs promoted the proliferation of resting lymphocytes, activated CD4+ and CD8+ T cells, and upregulated and activated Treg cells without any additional stimulation. In addition, iPSC-MSCs balanced biased TH1/TH2 cytokine levels. Cell–cell contact was confirmed to be a possible mechanism involved. NF-κB was identified to play an important role in the immunomodulatory effects of iPSC-MSCs on quiescent T cells. Conclusions iPSC-MSCs activate quiescent T cells and elevate regulatory T-cell response in AR patients, suggesting different immunomodulatory functions of iPSC-MSCs according to the phases of diseases. Therefore, iPSC-MSCs are a potential therapeutic candidate for treating allergic airway inflammation.

【 授权许可】

Unknown